Services

  • Home
  • Prostate Cancers

Prostate Cancers

Prostate cancer is cancer that occurs in the prostate. The prostate is a small walnut-shaped gland in males that produces the seminal fluid that nourishes and transports sperm.
Prostate cancer is one of the most common types of cancer. Many prostate cancers grow slowly and are confined to the prostate gland, where they may not cause serious harm. However, while some types of prostate cancer grow slowly and may need minimal or even no treatment, other types are aggressive and can spread quickly.
Prostate cancer that's detected early when it's still confined to the prostate gland has the best chance for successful treatment.

Symptoms

Prostate cancer may cause no signs or symptoms in its early stages.

  • Trouble urinating
  • Decreased force in the stream of urine
  • Blood in the urine
  • Blood in the semen
  • Bone pain
  • Losing weight without trying
  • Erectile dysfunction

Causes

Doctors know that prostate cancer begins when cells in the prostate develop changes in their DNA. A cell's DNA contains the instructions that tell a cell what to do. The changes tell the cells to grow and divide more rapidly than normal cells do. The abnormal cells continue living, when other cells would die.
The accumulating abnormal cells form a tumor that can grow to invade nearby tissue. In time, some abnormal cells can break away and spread to other parts of the body.

Dr. Avinash Talele

Dr Avinash D Talele MD DM is a Senior Medical Oncologist and Hematologist. Dr Avinash started his oncology carrier at prestigious Tata Memorial Hospital, Mumbai from 2011. He had the privilege to work with some of the finest oncologist in the country.

GET AN Profile!

Dr Avinash D Talele MD DM is a Senior Medical Oncologist and Hematologist. Dr Avinash started his oncology carrier at prestigious Tata Memorial Hospital, Mumbai from 2011. He had the privilege to work with some of the finest oncologist in the country, there he was trained to manage difficult cancers including lymphomas, myelomas, and rare uncommon malignancies with state of art protocols.